IDEMIA
14.12.2020 10:32:12 CET | Business Wire | Press release
IDEMIA:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005279/en/
Security and convenience at the heart of the Icelandic project
By 2022, new EU-EES regulations will require that biometric data, including face and fingerprints, of Third Country Nationals (TCNs) be captured and identified at the Schengen Area’s external borders. This will affect border check processes for all Schengen Member States.
With 20%-a-year air traffic growth (prior to COVID-19), Iceland planned to implement a program to manage increased passenger flows primarily in Iceland’s main international airport Keflavik, where 95% of the country’s largely non EU arriving and exiting passengers pass, and also in the country’s 30 seaports defined as external sea border crossing points. The new border management systems and equipment will also contribute to inland control within the Schengen Area.
Iceland, innovation partner in border management
IDEMIA will leverage its best-in-class biometric and border control expertise to uphold and upgrade Iceland’s border security. Meanwhile, this cutting-edge technology will contribute to more secured external borders and optimize the passenger flow by the use of the newest technology in border management.
This new border management system, based on IDEMIA’s Augmented Borders™ solution, will be compliant with EU-EES regulations. IDEMIA will also equip Icelandic border crossing points with its TravelKiosk™ EU-EES, the latest generation of user-centric multi-biometric border self-service kiosks . Also including automated TraveLane™ eGates, the entire system will boost throughput and convenience of passengers as they go through border controls. Lastly, to complete this end-to-end solution, IDEMIA will ensure that operator-manned counters, mobile solutions and tracking systems are set up to fit the requirements of the Icelandic Police with a view to shortening response times and improving coordination.
“The National Commissioner of the Icelandic Police, the Metropolitan Police and Sudurnes District police have from early 2019 been working on the implementation of EES in Iceland in close cooperation with Isavia. The procurement procedure started in September 2019 and today we have reached an important milestone by selecting IDEMIA as the supplier and future partner for the implementation of EES in Iceland. The police and Isavia place a high expectation to the collaboration with IDEMIA in the development of solutions that will improve border security and the traveler experience,” said Jón Pétur Jónsson , Chief Superintendent, at the National Commissioner of the Icelandic Police.
“ Isavia is truly excited about this co-operation with IDEMIA and the Icelandic Police. This is an important step in improving the performance and customer experience of the convenient and easy hub connection between Europe and North America, ” says Guðmundur Daði Rúnarsson , Chief Commercial and Airport Development Officer at Isavia. “ The Entry Exit system will affect all airports with traffic crossing external borders. Isavia is confident that implementing IDEMIA’s self service solutions in co-operation with the border police, will result in a more secure and efficient border crossing point, giving Keflavik the potential to grow even further in its Hub operation. ”
“IDEMIA is proud to accompany Iceland as one of the first countries of the Schengen Area to transform its border control system to comply with the European Entry/Exit System. We are determined to provide a comprehensive set of multi-biometric solutions that will give the assurance of a future-proof program, making Iceland our innovation partner in the implementation of the EU-EES. Our advanced border management solutions, based on a 40-year relationship with governments, will offer a better user experience by interactively adapting the border process per traveler category, while ensuring maximum security,” said Philippe Barreau , Executive Vice President for Public Security & Identity activities at IDEMIA.
As world leader in government identity and police biometric systems, IDEMIA brings to the table its cutting-edge technology and know-how so that personal identity is checked in the most secure way.
Recently, IDEMIA, in partnership with Sopra Steria, was selected to roll out the shared Biometric Matching System - the new European automated multi-biometric identification system for foreign nationals hosted by EU agency eu-LISA. Having partnered with EU institutions for many years and installed border control systems in more than 23 countries, IDEMIA’s comprehensive package meets the complex requirements of border control authorities, topped off by state-of-the-art technology.
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com or follow @IDEMIAGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005279/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
